Lipid-mediated steatosis sensitises hepatocytes to the adverse effects of doxorubicin
E-MTAB-3523 · ArrayExpress
TL;DR — A 92.9 MB bulk RNA-seq deposit (E-MTAB-3523, 38 file(s), liver) in the MASLD / NAFLD / NASH data lake. new MASLD bulk-RNAseq deposit.
0. Summary
Biological premise.
The following premise is sourced from the repository record (not fabricated).
The incidence of obesity and its related morbidities has rapidly increased over the past twenty years. One consequence of this is the increased probability of having to treat obese individuals for breast cancer. An important co-morbidity associated with obesity are the spectrum of fatty liver diseases. As such, an important question is how treatment of breast cancer with standard therapeutic agents may alter in individuals with fatty liver disease. Such impacts could result in an enhanced adverse effect profile over both acute (e.g. increased cytotoxicity against non-malignant tissues) or chronic (e.g. increased progression through the fatty liver disease spectrum) time periods. In this work we examine if lipid loading in human hepatocytes, leading to a steatotic phenotype, results in an altered toxic liability for the cancer therapeutic doxorubicin. We demonstrate that there is a synergistic impact on cytotoxicity, due to increased oxidative stress. Array analysis reveals the cellular changes associated with hepatocyte adaptation to lipid loading or doxorubicin treatment alone, and how these profiles are significantly altered during doxorubicin treatment of lipid-loaded hepatocytes. Such alterations, we believe, not only underlie the enhanced sensitivity of obese individuals to the acute adverse effects of doxorubicin, but may also potentiate transition along the fatty liver disease spectrum.Experimental design: Huh7 cells were exposed to lipid and/or doxorubicin as required. Huh7 cells were treated with vehicle control or 300 μM FFA mixture for 24 h in T25 culture flasks. The following day, the cells were treated with either 300 μM FFA mixture, 0.1 μM or 3.6 μM DOX and incubated for 4 hrs or 12 hrs. By the end of incubation time, Total RNA was extracted from cells using the RNeasy Plus Mini Kit (QIAGEN-UK) according to the instructions of manufacturer. RNA samples were sent to the Central Biotechnology Services (Cardiff University, UK), for quality control, synthesis of biotin-labeled cRNA, and hybridisation against Illumina Human-HT12 (Illumina, Inc., Hayward, CA) chips. Washed chips were scanned with Bead Station 500x (Illumina) and the signal intensities quantified with BeadStudio (Illumina). To ensure high quality results from the microarray data, RNA samples were extracted from three independent treatments, giving a biological n = 3 per treatment which gives statistical power to increase the confidence of the results/conclusions generated from the microarray experiment.
Study design (repository-stated): transcription profiling by array
Every file in this dataset is a bulk RNA-seq readout relevant to MASLD / non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), landed from ArrayExpress.
Assay and processing.
Modality: bulk RNA-seq (repository subtype: bulk-RNAseq). Tier-1 (must-have) for this modality = raw/normalized gene × sample expression matrix + per-sample design; Tier-2 (recommended) = author DE tables, design/contrasts, gene annotation; Tier-3 (optional / raw) = raw reads (FASTQ/BAM in SRA/ENA), reference build + quantifier version. The Completeness line in each dataset block below states, measured from the landed files, which tiers are present.
Sources.
- E-MTAB-3523 — ArrayExpress deposit (new MASLD bulk-RNAseq deposit).
- PMIDs: none recorded in the index for this deposit.
| Disease | MASLD / NAFLD / NASH |
| Assay / modality | bulk RNA-seq — bulk-RNAseq |
| Organisms | unspecified |
| Repository | ArrayExpress — EBI BioStudies |
| Accession | E-MTAB-3523 |
| Access | Public (open); files mirrored in this dataset's input/ folder. |
| Number of studies | 1 |
| Number of files | 38 |
| Total size | 92,868,472 bytes (≈ 92.9 MB) |
1. Datasets — sample sources, protocols, experiment design and metadata
Landed sources at a glance.
| Source | Access | Files |
|---|---|---|
| ArrayExpress | public / OPEN-processed | 38 |
The deposit at a glance.
| Accession | Description | Organism | Samples | Scale |
|---|---|---|---|---|
| E-MTAB-3523 | new MASLD bulk-RNAseq deposit | unspecified | n/a | 38 files · 92.9 MB |
E-MTAB-3523 — Lipid-mediated steatosis sensitises hepatocytes to the adverse effects of doxorubicin
ArrayExpress record · 38 files · 92.9 MB
-
Sample source. unspecified material; MASLD/NAFLD/NASH context (new MASLD bulk-RNAseq deposit).
-
Samples and retention. Sample count not declared in the repository index; see the per-sample metadata file(s) listed below.
-
Experiment design. Repository subtype: bulk-RNAseq; disease context MASLD/NAFLD/NASH.
-
Metadata available. Measured column names from
E-MTAB-3523.sdrf.txt:Source Name,Characteristics[organism],Characteristics[cell line],Material Type,Protocol REF,Protocol REF,Extract Name,Protocol REF,Labeled Extract Name,Label,Protocol REF,Assay Name,Technology Type,Array Design REF,Term Source REF,Array Data File,Comment [ArrayExpress FTP file],Factor Value[compound],Factor Value[dose],Unit[dose unit],Factor Value[time],Unit[time unit]. -
Files (annotated).
File What it is 9425128008_A_Grn.idatData file 9425128008_B_Grn.idatData file 9425128008_C_Grn.idatData file 9425128008_D_Grn.idatData file 9425128008_E_Grn.idatData file 9425128008_F_Grn.idatData file 9425128008_G_Grn.idatData file 9425128008_H_Grn.idatData file 9425128008_I_Grn.idatData file 9425128008_J_Grn.idatData file 9425128008_K_Grn.idatData file 9425128008_L_Grn.idatData file 9425128023_A_Grn.idatData file 9425128023_B_Grn.idatData file 9425128023_C_Grn.idatData file 9425128023_D_Grn.idatData file 9425128023_E_Grn.idatData file 9425128023_F_Grn.idatData file 9425128023_G_Grn.idatData file 9425128023_H_Grn.idatData file 9425128023_I_Grn.idatData file 9425128023_J_Grn.idatData file 9425128023_K_Grn.idatData file 9425128023_L_Grn.idatData file 9425128030_A_Grn.idatData file 9425128030_B_Grn.idatData file 9425128030_C_Grn.idatData file 9425128030_D_Grn.idatData file 9425128030_E_Grn.idatData file 9425128030_F_Grn.idatData file 9425128030_G_Grn.idatData file 9425128030_H_Grn.idatData file 9425128030_I_Grn.idatData file 9425128030_J_Grn.idatData file 9425128030_K_Grn.idatData file 9425128030_L_Grn.idatData file E-MTAB-3523.idf.txtArrayExpress Investigation Description Format — study design, protocol descriptions, contacts, publication (34 data rows × 2 cols) E-MTAB-3523.sdrf.txtArrayExpress Sample-and-Data Relationship Format — per-sample↔run table: characteristics, library geometry, archive/FASTQ links (36 data rows × 22 cols) -
How this experiment became a dataset. E-MTAB-3523 resolved via the ArrayExpress record API → 38 open file(s) fetched into this dataset's
input/folder → sizes verified on disk (92,868,472 bytes (≈ 92.9 MB)). -
Completeness (bulk RNA-seq). Present: per-sample design (Tier-1). Not detected among landed files: expression matrix (Tier-1). (Tiers per the matching modality skill; assessment measured from landed filenames/headers.)
2. Analyses this atlas supports
- Differential expression. Start from
9425128008_A_Grn.idat(expression matrix) +E-MTAB-3523.sdrf.txt(per-sample design) to run DESeq2/edgeR or limma contrasts and MASLD signatures. - Cross-cohort MASLD integration. Combine this deposit (E-MTAB-3523) with other liver/MASLD datasets in the lake sharing the same modality for meta-analysis.
Reproduce. All files are in this dataset's input/ folder; the source of record is E-MTAB-3523 (https://www.ebi.ac.uk/biostudies/studies/E-MTAB-3523). Re-fetch with the MASLD crawler (masld_download_pass.py --only E-MTAB-3523); sizes are verified on disk and recorded in this dataset's metadata.json.
Citation
Lipid-mediated steatosis sensitises hepatocytes to the adverse effects of doxorubicin. ArrayExpress accession E-MTAB-3523. https://www.ebi.ac.uk/biostudies/studies/E-MTAB-3523
About this dataset
This 10x Genomics dataset provides single-cell gene expression from liver samples, with disease state recorded as MASLD/NAFLD/NASH.
Analyze it in Drylab
Open this dataset in Drylab and ask a question in plain language. The AI agent loads the files, runs the analysis in a ready sandbox and explains each result. A typical first pass:
- Load the filtered feature-barcode matrix (HDF5) and run quality control on counts, genes and mitochondrial reads per cell.
- Normalize, select variable genes, then cluster the cells and draw a UMAP.
- Annotate clusters with marker genes and compare the cell-type mix between conditions.
- Run differential expression between cell types or samples to characterize masld/nafld/nash biology.